Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Associated Ophthalmopathies
Thyroid-Associated Ophthalmopathy

Interventions

DRUG: teprotumumab
DRUG: normal saline

Sponsor

Amgen